Developer docs
API playgroundTry for free, no card

Search company profiles

LoValTech

Full company profile

uuid0003nq5

Namestring
LoValTech
Legal namestring
lovaltech
Company typeenum
Private
Founded yearint
2022
Descriptiontext

LoValTech is a French DeepTech biotech startup, founded in January 2022 as a spin-off from the BioMAP research team (UMR ISP 1282) at the University of Tours and INRAE, headquartered in Tours, France. The company develops nasal protein subunit vaccines built around three integrated technology components: a multivalent fusion protein (SwFN) combining SARS-CoV-2 Spike and Nucleocapsid, proprietary mucosal nanocarriers, and a novel muco-excipient delivery system that is adjuvant-free and stable at positive temperatures. The lead candidate, LVT-001 (MUCOBOOST), is a nasal COVID-19 vaccine designed to induce both systemic IgG and mucosal IgA responses, with the goal of achieving sterilizing immunity and blocking viral transmission at the respiratory entry point. Preclinical data, published in npj Vaccines (Nature), demonstrated cross-reactive immunity against variants and reduced host-to-host transmission in hamster models.

The business model is structured around three revenue streams that activate post-approval: direct vaccine sales to healthcare systems and governments, licensing and royalty agreements with pharmaceutical partners for global commercialization, and government/institutional procurement for pandemic preparedness. Manufacturing is outsourced to a network of French CDMOs (GTP Bioways for protein, Stanipharm for muco-excipient, C-Ris Pharma for preclinical studies), while nasal spray device production is being built in partnership with Aptar Pharma under the France 2030 program. The company has secured over €16 million in public funding (MESRI, ANRS-MIE, France 2030, i-Lab) plus an undisclosed seed round, and is currently raising €5M through the Tudigo crowdfunding platform. As of 2026, Phase I of the MUCOBOOST clinical trial has been successfully completed (demonstrating excellent tolerability), Phase II is underway under ANSM authorization (NCT06821126), and the broader mucosal platform is positioned for extension into influenza, bronchiolitis, malaria, oncology, and allergy indications.

Short descriptiontext

LoValTech is a French DeepTech biotech developing nasal protein subunit vaccines via a proprietary mucosal delivery platform. Its lead candidate LVT-001/MUCOBOOST targets COVID-19 in Phase II trials, with commercialization planned through pharmaceutical licensing and sales to healthcare systems and governments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTours, France
HQ citystring
Tours
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nasal vaccine development, mucosal immunity platform, protein subunit vaccines, intranasal drug delivery, biopharmaceutical research
Industry3 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAK
Vaccine Cold Chain, Storage & Distribution
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Nasal Vaccines
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Vaccine Product Sales
TypeOne Time License
Description

Revenue from direct sales of nasal vaccines to healthcare systems, governments, and distribution networks upon regulatory approval and commercialization.

lovaltechnology.com
2Licensing Agreements
TypeLicensing Royalties
Description

Value-creation strategy based on clinical milestones and licensing agreements with pharmaceutical industrial partners for vaccine development and commercialization rights.

lovaltechnology.com
3Government/Institutional Procurement
TypeSubscription Recurring
Description

Public funding and procurement contracts from governments and health authorities for pandemic preparedness and national vaccination programs.

lovaltechnology.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

LoValTech develops a new generation of nasally-administered protein subunit vaccines using a proprietary muco-excipient delivery platform combined with multivalent fusion proteins (spike and nucleoprotein). The lead product, LVT-001/MUCOBOOST, is a nasal COVID-19 vaccine designed to induce both systemic and mucosal immunity, blocking viral transmission and protecting against current and emerging variants. The platform technology is being extended to influenza, bronchiolitis, malaria, and other respiratory infectious diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Significant reduction in viral load and transmission demonstrated in preclinical models published in npj Vaccines (Nature)
+4 more records
Product overview1 text field

LoValTech is a French DeepTech biotech company developing a new generation of nasally-administered protein vaccines. The company's flagship product is LVT-001 (MUCOBOOST), a COVID-19 nasal vaccine using a proprietary muco-excipient platform combined with a multivalent fusion protein (Spike + nucleoprotein). The platform technology enables broad-spectrum protection against variants by inducing both systemic and mucosal immunity, with the nasal spray delivery system allowing non-invasive administration. The company is advancing Phase I/II clinical trials for its lead vaccine candidate while building a versatile mucosal vaccine platform applicable to multiple diseases including influenza and malaria.

Product and service4 records
1LVT-001 / MUCOBOOST
Categorycore product
Description

Nasal subunit vaccine against COVID-19 composed of a multivalent fusion protein (SwFN) combining Spike and nucleoprotein with biocompatible mucosal nanocarriers (Nc). Designed to induce both systemic and mucosal immunity, blocking viral transmission and protecting against current and emerging SARS-CoV-2 variants.

2Muco-excipient Platform
Categoryplatform technology
Description

Proprietary mucosal excipient technology enabling optimal vaccine delivery in the nasal cavity. The adjuvant-free formulation allows robust humoral and cellular immune response induction. Developed under GMP conditions.

3Nasal Spray Delivery System
Categorycore product
Description

Non-invasive intranasal spray device for vaccine administration. Developed in collaboration with Aptar Pharma, a world leader in pharmaceutical sprays and aerosols. Enables easy self-administration without needles.

4Intranasal Spike and Nucleoprotein Fusion Protein Vaccine
Categorysub-product
Description

Broad-spectrum vaccine candidate published in npj Vaccines (Nature) demonstrating cross-protection against SARS-CoV-2 variants and reduced host-to-host transmission in preclinical models.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-26
Description

World leader in spray and aerosol manufacturing for pharmaceutical market. Developing unprecedented nasal spray device design per LovalTech specifications. Committed to dedicated production line in France under France 2030 program.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

The BioMAP research team (UMR ISP 1282) developed the nasal vaccine technology. LovalTech was created to pursue industrial development. Includes scientific founders Isabelle Dimier-Poisson, Mathieu Epardaud, and Nicolas Aubrey from the university team. The university team has published 30+ articles and filed 5 patents in 5 years.

Strategic tierMajorTypeTechnology or Integration
Description

Contract Development and Manufacturing Organization (CDMO) for GMP production and pharmaceutical release of vaccine protein.

4Stanipharm
Strategic tierMajorTypeTechnology or Integration
Description

CDMO for GMP production and pharmaceutical release of muco-excipient.

lovaltechnology.com
Strategic tierMajorTypeTechnology or Integration
Description

French CRO specialized in non-clinical studies. Conducted regulatory toxicity and immunogenicity studies from October 2022, now completed and validated vaccine safety.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage US biotech developing intranasal vaccines including T-COVID (AdCOVID) and NasoShield for anthrax, with direct comparison to LoValTech's mucosal vaccine platform targeting respiratory pathogens.

TypeDirect peer
Description

Clinical-stage biotech using live-attenuated intranasal vaccines for COVID-19 (COVI-VAC), influenza, and RSV, with a comparable mucosal vaccine platform approach and similar target indications.

TypeDirect peer
Description

Clinical-stage biotech developing oral tablet vaccines targeting mucosal immunity for COVID-19 and norovirus, competing in the same mucosal immunity differentiation thesis as LoValTech.

TypeDirect peer
Description

Clinical-stage biotech developing intranasal vaccines using a proprietary platform (including a parainfluenza-based vector for respiratory syncytial virus), with comparable mucosal delivery approach.

TypeDirect peer
Description

Clinical-stage biotech developing intranasal live-attenuated vaccines for RSV and COVID-19, targeting mucosal immunity at the point of viral entry similar to LoValTech's mechanism.

TypeDirect peer
Description

Chinese biotech that launched Convidecia Air, the first approved inhaled/admistered intranasal COVID-19 vaccine, representing the most advanced commercial competitor in the mucosal COVID vaccine space.

TypeDirect peer
Description

Indian vaccine manufacturer with iNCOVACC, an approved intranasal adenoviral COVID-19 vaccine, providing an established commercial benchmark for mucosal COVID vaccine commercialization.

TypeBroad incumbent
Description

Through acquisition of MedImmune, markets FluMist — the most established intranasal vaccine (live-attenuated influenza) — representing the incumbent mucosal vaccine platform against which LoValTech must differentiate.

TypeEmerging player
Description

Clinical-stage biotech developing intranasal M2SR flu vaccine that demonstrates comparable mucosal immunity approach and applies broadly to the respiratory vaccine market LoValTech targets.

TypeEmerging player
Description

Clinical-stage biotech developing intranasal vaccines using a nanoemulsion platform for infectious disease indications, an emerging competitor in the mucosal vaccine delivery space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LoValTech

Nasal Vaccineslovaltechnology.com

LoValTech is a French DeepTech biotech developing nasal protein subunit vaccines via a proprietary mucosal delivery platform. Its lead candidate LVT-001/MUCOBOOST targets COVID-19 in Phase II trials, with commercialization planned through pharmaceutical licensing and sales to healthcare systems and governments.

What LoValTech does

LoValTech is a French DeepTech biotech startup, founded in January 2022 as a spin-off from the BioMAP research team (UMR ISP 1282) at the University of Tours and INRAE, headquartered in Tours, France. The company develops nasal protein subunit vaccines built around three integrated technology components: a multivalent fusion protein (SwFN) combining SARS-CoV-2 Spike and Nucleocapsid, proprietary mucosal nanocarriers, and a novel muco-excipient delivery system that is adjuvant-free and stable at positive temperatures. The lead candidate, LVT-001 (MUCOBOOST), is a nasal COVID-19 vaccine designed to induce both systemic IgG and mucosal IgA responses, with the goal of achieving sterilizing immunity and blocking viral transmission at the respiratory entry point. Preclinical data, published in npj Vaccines (Nature), demonstrated cross-reactive immunity against variants and reduced host-to-host transmission in hamster models.

The business model is structured around three revenue streams that activate post-approval: direct vaccine sales to healthcare systems and governments, licensing and royalty agreements with pharmaceutical partners for global commercialization, and government/institutional procurement for pandemic preparedness. Manufacturing is outsourced to a network of French CDMOs (GTP Bioways for protein, Stanipharm for muco-excipient, C-Ris Pharma for preclinical studies), while nasal spray device production is being built in partnership with Aptar Pharma under the France 2030 program. The company has secured over €16 million in public funding (MESRI, ANRS-MIE, France 2030, i-Lab) plus an undisclosed seed round, and is currently raising €5M through the Tudigo crowdfunding platform. As of 2026, Phase I of the MUCOBOOST clinical trial has been successfully completed (demonstrating excellent tolerability), Phase II is underway under ANSM authorization (NCT06821126), and the broader mucosal platform is positioned for extension into influenza, bronchiolitis, malaria, oncology, and allergy indications.

LoValTech firmographics

Firmographics
Name
LoValTech
Legal name
lovaltech
Website
https://lovaltechnology.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
LoValTech is a French DeepTech biotech developing nasal protein subunit vaccines via a proprietary mucosal delivery platform. Its lead candidate LVT-001/MUCOBOOST targets COVID-19 in Phase II trials, with commercialization planned through pharmaceutical licensing and sales to healthcare systems and governments.
Ownership category
akta.pro rank

LoValTech industry classification

Industry
Product category
Nasal Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAK
Vaccine Cold Chain, Storage & Distribution

Keywords

  • Nasal vaccine development
  • Mucosal immunity platform
  • Protein subunit vaccines
  • Intranasal drug delivery
  • Biopharmaceutical research

Where LoValTech is headquartered

Location

Headquarters

HQ city
Tours
HQ country
France
HQ region
Europe

Offices1 record

Markets served

LoValTech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Vaccine Product Sales: Revenue from direct sales of nasal vaccines to healthcare systems, governments, and distribution networks upon regulatory approval and commercialization.
  2. Licensing Agreements: Value-creation strategy based on clinical milestones and licensing agreements with pharmaceutical industrial partners for vaccine development and commercialization rights.
  3. Government/Institutional Procurement: Public funding and procurement contracts from governments and health authorities for pandemic preparedness and national vaccination programs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

LoValTech product offering

Product offering

Core offering

LoValTech develops a new generation of nasally-administered protein subunit vaccines using a proprietary muco-excipient delivery platform combined with multivalent fusion proteins (spike and nucleoprotein). The lead product, LVT-001/MUCOBOOST, is a nasal COVID-19 vaccine designed to induce both systemic and mucosal immunity, blocking viral transmission and protecting against current and emerging variants. The platform technology is being extended to influenza, bronchiolitis, malaria, and other respiratory infectious diseases.

Product overview

LoValTech is a French DeepTech biotech company developing a new generation of nasally-administered protein vaccines. The company's flagship product is LVT-001 (MUCOBOOST), a COVID-19 nasal vaccine using a proprietary muco-excipient platform combined with a multivalent fusion protein (Spike + nucleoprotein). The platform technology enables broad-spectrum protection against variants by inducing both systemic and mucosal immunity, with the nasal spray delivery system allowing non-invasive administration. The company is advancing Phase I/II clinical trials for its lead vaccine candidate while building a versatile mucosal vaccine platform applicable to multiple diseases including influenza and malaria.

Differentiator

Problem solved

Functional benefit

Products and services

  • LVT-001 / MUCOBOOST Nasal subunit vaccine against COVID-19 composed of a multivalent fusion protein (SwFN) combining Spike and nucleoprotein with biocompatible mucosal nanocarriers (Nc). Designed to induce both systemic and mucosal immunity, blocking viral transmission and protecting against current and emerging SARS-CoV-2 variants.
  • Muco-excipient Platform Proprietary mucosal excipient technology enabling optimal vaccine delivery in the nasal cavity. The adjuvant-free formulation allows robust humoral and cellular immune response induction. Developed under GMP conditions.
  • Nasal Spray Delivery System Non-invasive intranasal spray device for vaccine administration. Developed in collaboration with Aptar Pharma, a world leader in pharmaceutical sprays and aerosols. Enables easy self-administration without needles.
  • Intranasal Spike and Nucleoprotein Fusion Protein Vaccine Broad-spectrum vaccine candidate published in npj Vaccines (Nature) demonstrating cross-protection against SARS-CoV-2 variants and reduced host-to-host transmission in preclinical models.

Quantifiable outcome

  • Significant reduction in viral load and transmission demonstrated in preclinical models published in npj Vaccines (Nature)
  • +4 more outcomes

Companies that use LoValTech

Customer profile

Segments3 records

Ideal customer profiles2 records

LoValTech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

LoValTech partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • Aptar PharmacoreStrategic or Co-development Partner · 26 September 2023World leader in spray and aerosol manufacturing for pharmaceutical market. Developing unprecedented nasal spray device design per LovalTech specifications. Committed to dedicated production line in France under France 2030 program.
  • BioMAP (University of Tours / INRAE)coreStrategic or Co-development Partner · 1 January 2022The BioMAP research team (UMR ISP 1282) developed the nasal vaccine technology. LovalTech was created to pursue industrial development. Includes scientific founders Isabelle Dimier-Poisson, Mathieu Epardaud, and Nicolas Aubrey from the university team. The university team has published 30+ articles and filed 5 patents in 5 years.
  • GTP BiowaysmajorTechnology or IntegrationContract Development and Manufacturing Organization (CDMO) for GMP production and pharmaceutical release of vaccine protein.
  • StanipharmmajorTechnology or IntegrationCDMO for GMP production and pharmaceutical release of muco-excipient.
  • C-Ris PharmamajorTechnology or IntegrationFrench CRO specialized in non-clinical studies. Conducted regulatory toxicity and immunogenicity studies from October 2022, now completed and validated vaccine safety.

Scale indicators11 records

Recent moves4 records

Expansion highlights6 records

LoValTech competitors and assessment

Company assessment

Direct peers

  • Altimmune: Clinical-stage US biotech developing intranasal vaccines including T-COVID (AdCOVID) and NasoShield for anthrax, with direct comparison to LoValTech's mucosal vaccine platform targeting respiratory pathogens.
  • Codagenix: Clinical-stage biotech using live-attenuated intranasal vaccines for COVID-19 (COVI-VAC), influenza, and RSV, with a comparable mucosal vaccine platform approach and similar target indications.
  • Vaxart: Clinical-stage biotech developing oral tablet vaccines targeting mucosal immunity for COVID-19 and norovirus, competing in the same mucosal immunity differentiation thesis as LoValTech.
  • CyanVac: Clinical-stage biotech developing intranasal vaccines using a proprietary platform (including a parainfluenza-based vector for respiratory syncytial virus), with comparable mucosal delivery approach.
  • Meissa Vaccines: Clinical-stage biotech developing intranasal live-attenuated vaccines for RSV and COVID-19, targeting mucosal immunity at the point of viral entry similar to LoValTech's mechanism.
  • CanSino Biologics: Chinese biotech that launched Convidecia Air, the first approved inhaled/admistered intranasal COVID-19 vaccine, representing the most advanced commercial competitor in the mucosal COVID vaccine space.
  • Bharat Biotech: Indian vaccine manufacturer with iNCOVACC, an approved intranasal adenoviral COVID-19 vaccine, providing an established commercial benchmark for mucosal COVID vaccine commercialization.

Broad incumbents

  • AstraZeneca (FluMist): Through acquisition of MedImmune, markets FluMist — the most established intranasal vaccine (live-attenuated influenza) — representing the incumbent mucosal vaccine platform against which LoValTech must differentiate.

Emerging players

  • FluGen: Clinical-stage biotech developing intranasal M2SR flu vaccine that demonstrates comparable mucosal immunity approach and applies broadly to the respiratory vaccine market LoValTech targets.
  • BlueWillow Biologics: Clinical-stage biotech developing intranasal vaccines using a nanoemulsion platform for infectious disease indications, an emerging competitor in the mucosal vaccine delivery space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

LoValTech social profiles

Digital presence

LoValTech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LoValTech leadership team

Management profile

Number of profiles

Profiles10 records

LoValTech funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LoValTech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LoValTech

What does LoValTech do?

LoValTech develops a new generation of nasally-administered protein subunit vaccines using a proprietary muco-excipient delivery platform combined with multivalent fusion proteins (spike and nucleoprotein). The lead product, LVT-001/MUCOBOOST, is a nasal COVID-19 vaccine designed to induce both systemic and mucosal immunity, blocking viral transmission and protecting against current and emerging variants. The platform technology is being extended to influenza, bronchiolitis, malaria, and other respiratory infectious diseases.

Is LoValTech a public or private company?

LoValTech is a private company. It is classified as venture growth investor backed and is currently operating.

When was LoValTech founded?

LoValTech was founded in 2022. It employs 1 to 10 people.

Where is LoValTech based?

LoValTech is headquartered in Tours, France, in the Europe region.

How does LoValTech make money?

Three revenue lines are on record. Vaccine Product Sales are the primary driver. The others are licensing Agreements and government/Institutional Procurement.

Who are LoValTech's main competitors?

Direct peers on record are Altimmune, Codagenix, Vaxart, CyanVac, Meissa Vaccines, CanSino Biologics and Bharat Biotech. AstraZeneca (FluMist) is listed as a broad incumbent. Emerging players are FluGen and BlueWillow Biologics.

Does LoValTech have an API?

No public API is recorded for LoValTech.

What industry is LoValTech in?

LoValTech's product category is Nasal Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAF, Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
La Gazette du LABORATOIRELoValTech et Aptar Pharma lauréats de France 2030LoValTech and Aptar Pharma have been selected as winners of the France 2030 program to receive €8.4 million in funding for developing a nasal vaccine combined with a dedicated medical device. The project aims to validate the formulation, develop the delivery system, and conduct Phase I and II clinical trials for LoValTech's novel protein-based vaccines targeting diseases like COVID-19. This support from the French government initiative is intended to accelerate the emergence of unique French vaccination technology.MaddynessLoValTech en première ligne pour proposer un vaccin nasal contre le Covid-19 et les futures maladies infectieusesFrench deeptech LoValTech is developing a nasal protein vaccine for SARS-CoV-2 and other infectious diseases, aiming for market entry in 2025 or 2026 after clinical trials begin in 2024. The company secured 11 million euros in funding, including support from the France 2030 program, and partnered with Aptar Pharma to develop the administration device. This technology aims to induce mucosal immunity to block virus transmission and eliminate the need for extreme cold storage.EconomicnewsobserverLoValTech et Aptar Pharma, lauréats de France 2030LoValTech and Aptar Pharma have been selected as winners of the France 2030 program to receive €8.4 million in funding for their MUCOVAC 2.0 project, which aims to develop a nasal vaccine against COVID-19 and other infectious diseases. This financial support will enable the companies to validate manufacturing formulations, develop nasal delivery devices, and conduct Phase I and II clinical trials. The initiative is part of the French government's broader strategy to boost health innovation and sovereignty within Europe.